The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Verona Pharma Rises After Huge Fundraise

Fri, 17th Jul 2020 10:49

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - WINNERS

----------

Homeserve, up 2.7%. The home emergency cover provider said its membership businesses, policy renewal and mid-term cancellation rates have all continued in line with historic trends in a "traditionally quieter period", spanning April to mid-July. The home repairs and improvements company added that it has felt no effects from Covid-19 and "customer satisfaction is at record highs" reflecting strong service levels during the pandemic. Homeserve has resumed mergers and acquisitions activity with a strong pipeline of targets and four profitable acquisitions completed in May and June, the most significant of these bringing 38,000 new policy customers in Spain. Walsall, England-based Homeserve continues to expect to deliver a solid performance in the year ending March 31, 2021.

----------

National Grid, up 2.0%. Deutsche Bank raised the UK power grid operator to Buy from Hold.

----------

Rio Tinto, up 1.7%. The Anglo-Australian miner left its annual guidance unchanged after posting mixed second-quarter production figures. Bauxite and iron ore output grew in the three months to June 30, though there was a double-digit fall in titanium dioxide slag production, figures from the miner showed. The FTSE 100-listed firm did edge its capital expenditure forecasts higher as the bite from Covid-19 eased and the dollar weakened. Pilbara iron ore production rose 4% year-on-year in the second quarter to 83.2 million tonnes, with shipments edging 1% higher to 86.7 million tonnes.

----------

FTSE 250 - WINNERS

----------

Renishaw, up 6.0%. The precision instruments maker raised its annual revenue forecast, but downgraded its profit estimate. Renishaw predicted revenue for the year to June 30, to be around GBP510 million. In May, it had guided for revenue in a range between GBP490 million to GBP505 million. However, Renishaw warned it will miss its annual pretax profit estimate due to GBP46 million in charges, but remains focused on cash preservation due to the Covid-19 pandemic. The company, which makes dental scanning products and precision measurement equipment, in May, had guided pretax profit for the financial year, to be in the range of GBP31 million and GBP41 million. It anticipates GBP24 million in restructuring costs and GBP22 million of fair value losses of financial instruments in financial 2020. In financial 2019, the company recorded pretax profit of GBP109.9 million on a revenue of GBP574.0 million. Adjusted pretax profit had totalled GBP103.9 million.

----------

Ninety One, up 2.2%. The money manager, formerly part of Investec, posted a double-digit climb in assets under management during its first-quarter. Assets under management rose 14% to GBP118.0 billion at June 30 from GBP103.4 billion at the end of March. The second quarter of 2020, the first quarter of Ninety One's 2021 financial year, saw equities bounce as easing Covid-19 restrictions in some areas improved risk sentiment.

---------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Verona Pharma, up 42%. The biopharmaceutical company said it has raised USD200 million in an oversubscribed private share placement and subscription. The fundraise comprises a private placement of 39.1 million American Depositary shares, each representing eight ordinary shares, at USD4.50 per ADS, and 43.1 million ordinary shares at the same issue price. Net proceeds of the financing is expected to total USD183 million, after deducting placement agent fees and estimated expenses. The issue price represents a discount of 4.7% to USD4.72 per ADS price on Wednesday. The company focused on respiratory diseases said it will use the proceeds to fund its phase 3 clinical program - Ensifentrine as a novel inhaled nebulized COPD therapy - in chronic obstructive pulmonary disease and for general corporate purposes. The trials are planned to start later in 2020.

----------

Pennant International, up 24%. The training and support services provider announced the winning of a new contract with an initial order value of GBP1.5 million. The award follows Pennant in February receiving a statement of intent for the purchase of training aids worth up to GBP5 million from a unnamed Middle East-based customer. The majority of revenue on the order is expected to be recognised in 2021 as the training aids are completed and delivered. The new contract award takes Pennant's contracted order book for 2021 to just under GBP13.5 million. Looking ahead, the group expects the customer to make further purchases, and anticipates another order to be placed either later in 2020 or early 2021.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
7 Mar 2014 09:39

Friday broker round-up UPDATE

AGA Rangemaster: N+1 Singer ups target price from 175p to 192p and maintains a buy recommendation. Aggreko: JP Morgan lowers target price from 1542p to 1536p and maintains a neutral rating. Goldman Sachs increases target price from 1876p to 1950p and keeps a buy recommendation. Numis upgrades to re

Read more
6 Mar 2014 18:02

Verona Pharma Looks To Raise Up To GBP14 Million In Share Placing

LONDON (Alliance News) - Verona Pharma PLC Thursday said it intends to raise up to GBP14 million before expenses in a share placing, subscription, and open offer, which it said it will use to fund further development of its RPL554 drug. The drug development company focuses on medicines to t

Read more
11 Nov 2013 08:50

Monday broker round-up UPDATE

Associated British Foods: Barclays downgrades to equal-weight with a target price of 2100p. Bovis Homes Group: Deutsche Bank moves target price from 1001p to 1008p maintaining a buy recommendation. British Land: Deutsche Bank downgrades to sell with a target price of 520p. British Sky Broadcastin

Read more
25 Oct 2013 08:35

Verona Pharma Says RPL554 Drug Trial Positive

Read more
30 Sep 2013 12:47

Verona Pharma Widens Losses As Treatment Development Continues

Read more
5 Sep 2013 09:37

Verona Pharma Appoints Chroma CEO Bungay As New Part-Time CFO

Read more
5 Sep 2013 08:15

Verona Pharma replaces CFO Lowe with Bungay

Verona Pharma on Thursday said Chief Financial Officer (CFO) Danny Lowe would be replaced by Richard Bungay with immediate effect. Bungay will work part-time at the respiratory treatments specialist at first and Lowe will work with him for an interim period to make sure there is a smooth handover.

Read more
23 Jul 2013 16:21

SABMilller Chairman sells over 11m pounds in shares

Graham Mackay, the Chairman of SABMiller who is currently on a medical leave of absence due to a brain tumour, has sold over 11m pounds-worth of shares in the company. Mackay sold a total of 350,000 shares between July 16-18th through three separate transactions, the firm revealed on Tuesday. He so

Read more
26 Apr 2013 15:09

Advanced Oncotherapy CEO makes triple purchase

The Chief Executive of Advanced Oncotherapy, a provider of new technology for innovative and patient-focused cancer treatments, has this week purchased three lots of shares in the group, taking his stake to just under 69.4m shares. On Thursday Sinclair purchased one round of 8.075m shares at 1.59p

Read more
10 Apr 2013 16:27

AZ Electronic Materials directors try to minimize damage

John Whybrow, the Chairman of AZ Electronic Materials, which on Tuesday tanked after it issued a warning on full year revenue, has shown his faith in the chemicals company by enlarging his shareholding. Whybrow acquired 40,000 shares at 254p each for a total trade value of £101,600, taking his sta

Read more
4 Sep 2012 08:58

Small caps round-up: Verona, Image Scan, Avia

Respiratory diseases specialist Verona Pharma has hailed a positive outcome of a clinical trial of its lead drug candidate, the snappily-named RPL554. The data showed that a single dose of RPL554 in spray form administered to patients with chronic obstructive pulmonary disease (COPD) produced a ra

Read more
28 Aug 2012 14:43

Small caps round-up: Transense Tech, Hightex, Verona Pharma

Transense Technologies, which provides sensor systems for the transportation and industrial markets, has reported that its trading division, Translogik, has received an initial order for its iTrack Tyre Temperature and Pressure Monitoring Systems for mining and off-the-road vehicles from its Indones

Read more
9 Jul 2012 10:25

Small caps round-up: Lighthouse, Verona Pharma, Manroy...

Shares in Lighthouse Group, the financial advice and wealth management group, plunged on Monday after the company proposed to cancel its listing on AIM. The group must receive approval from shareholders representing at least three-quarters of the company's shares for the cancellation to be approved.

Read more
26 Nov 2010 15:56

Small caps round-up: Verona Pharma, PHSC, Sterling Green

Verona Pharma, respiratory diseases treatment developer, is initiating a new higher dose trial of its lead drug, RPL554, in patients with asthma, after receiving the go-ahead from the Dutch authorities. The company also announced that it has completed proof of concept trials on delivering RPL554 vi

Read more
28 Jun 2010 07:33

Verona Pharma In Talks With Licensees For RPL554 Cough Project

LONDON (Dow Jones)--Verona Pharma PLC (VRP.LN), an AIM quoted drug discovery company, said Monday licensing discussions continue to advance with potential licensees for its RPL554 cough project and it plans three clinical trials to add value to licensing package for RPL554. MAIN FACTS: -Has

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.